Willem Corver

Dr. Willem Corver

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2000 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
LKLouise A. Koopman
Louise A. Koopman
WCWillem Corver
Willem Corver
ASArno R. van der Slik
Arno R. van der Slik
MGMarius J. Giphart
Marius J. Giphart
GFGert Jan Fleuren
Gert Jan Fleuren
The nature and frequency of human histocompatibility leukocyte antigen (HLA) class I loss mechanisms in primary cancers are largely unknown. We used flow cytometry and molecular analyses to concurrently assess allele-specific HLA phenotypes and genotypes in subpopulations from 30 freshly isolated cervical tumor cell suspensions. Tumor-associated HLA class I alterations were present in 90% of the lesions tested, comprising four altered pheno/genotype categories: (a) HLA-A or -B allelic loss (17%), mostly associated with gene mutations; (b) HLA haplotype loss, associated with loss of heterozygosity at 6p (50%). This category included cases with additional loss of a (third) HLA-A or -B allele due to mutation, as well as one case with an HLA class I–negative tumor cell subpopulation, caused by a β2-microglobulin gene mutation; (c) Total HLA class I antigen loss and retention of heterozygosity (ROH) at 6p (10%); and (d) B locus or HLA-A/B downregulation associated with ROH and/or allelic imbalance at 6p (10%). Normal HLA phenotypes and ROH at 6p were observed in 10% of the cases. One case could not be classified (3%). Altered HLA class I antigen expression occurs in most cervical cancers, is diverse, and is mainly caused by genetic changes. Combined with widespread tumor heterogeneity, these changes have profound implications for natural immunity and T cell–based immunotherapy in cervical cancer.

1 July 2016 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
GLGertjan Lugthart
Gertjan Lugthart
JMJanine E Melsen
Janine E Melsen
CVCarly Vervat
Carly Vervat
MDMonique M. van Ostaijen-Ten Dam
Monique M. van Ostaijen-Ten Dam
WCWillem Corver
Willem Corver
MSMarco W. Schilham
Marco W. Schilham
Knowledge of human NK cells is based primarily on conventional CD56bright and CD56dim NK cells from blood. However, most cellular immune interactions occur in lymphoid organs. Based on the coexpression of CD69 and CXCR6, we identified a third major NK cell subset in lymphoid tissues. This population represents 30–60% of NK cells in marrow, spleen, and lymph node but is absent from blood. CD69+CXCR6+ lymphoid tissue NK cells have an intermediate expression of CD56 and high expression of NKp46 and ICAM-1. In contrast to circulating NK cells, they have a bimodal expression of the activating receptor DNAX accessory molecule 1. CD69+CXCR6+ NK cells do not express the early markers c-kit and IL-7Rα, nor killer cell Ig-like receptors or other late-differentiation markers. After cytokine stimulation, CD69+CXCR6+ NK cells produce IFN-γ at levels comparable to CD56dim NK cells. They constitutively express perforin but require preactivation to express granzyme B and exert cytotoxicity. After hematopoietic stem cell transplantation, CD69+CXCR6+ lymphoid tissue NK cells do not exhibit the hyperexpansion observed for both conventional NK cell populations. CD69+CXCR6+ NK cells constitute a separate NK cell population with a distinct phenotype and function. The identification of this NK cell population in lymphoid tissues provides tools to further evaluate the cellular interactions and role of NK cells in human immunity.

1 June 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WCWillem Corver
Willem Corver
DRDina Ruano
Dina Ruano
KWKarin Weijers
Karin Weijers
WHWietske C. E. Den Hartog
Wietske C. E. Den Hartog
MNMerlijn P. van Nieuwenhuizen
Merlijn P. van Nieuwenhuizen
HMHans Morreau
Hans Morreau
Recurrent non-medullary thyroid carcinoma (NMTC) is a rare disease. We initially characterized 27 recurrent NMTC: 13 papillary thyroid cancers (PTC), 10 oncocytic follicular carcinomas (FTC-OV), and 4 non-oncocytic follicular carcinomas (FTC). A validation cohort composed of benign and malignant (both recurrent and non-recurrent) thyroid tumours was subsequently analysed (n = 20). Data from genome-wide SNP arrays and flow cytometry were combined to determine the chromosomal dosage (allelic state) in these tumours, including mutation analysis of components of PIK3CA/AKT and MAPK pathways. All FTC-OVs showed a very distinct pattern of genomic alterations. Ten out of 10 FTC-OV cases showed near-haploidisation with or without subsequent genome endoreduplication. Near-haploidisation was seen in 5/10 as extensive chromosome-wide monosomy (allelic state [A]) with near-haploid DNA indices and retention of especially chromosome 7 (seen as a heterozygous allelic state [AB]). In the remaining 5/10 chromosomal allelic states AA with near diploid DNA indices were seen with allelic state AABB of chromosome 7, suggesting endoreduplication after preceding haploidisation. The latter was supported by the presence of both near-haploid and endoreduplicated tumour fractions in some of the cases. Results were confirmed using FISH analysis. Relatively to FTC-OV limited numbers of genomic alterations were identified in other types of recurrent NMTC studied, except for chromosome 22q which showed alterations in 6 of 13 PTCs. Only two HRAS, but no mutations of EGFR or BRAF were found in FTC-OV. The validation cohort showed two additional tumours with the distinct pattern of genomic alterations (both with oncocytic features and recurrent). We demonstrate that recurrent FTC-OV is frequently characterised by genome-wide DNA haploidisation, heterozygous retention of chromosome 7, and endoreduplication of a near-haploid genome. Whether normal gene dosage on especially chromosome 7 (containing EGFR, BRAF, cMET) is crucial for FTC-OV tumour survival is an important topic for future research. Data are made available at GEO (GSE31828).

15 March 2007 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
AMAkash M. Mehta
Akash M. Mehta
Ekaterina S. JordanovaEkaterina S. Jordanova
Ekaterina S. Jordanova
TWTom Van Wezel
Tom Van Wezel
HUHae‐Won Uh
Hae‐Won Uh
WCWillem Corver
Willem Corver
GFGert J. Fleuren
Gert J. Fleuren

6 February 2009 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
AMAkash M. Mehta
Akash M. Mehta
Ekaterina S. JordanovaEkaterina S. Jordanova
Ekaterina S. Jordanova
WCWillem Corver
Willem Corver
TWTom Van Wezel
Tom Van Wezel
HUHae‐Won Uh
Hae‐Won Uh
GFGert Jan Fleuren
Gert Jan Fleuren

1 January 2007 in Clinical Cancer Research
Verified
Journal Article
Closed access
MBMarjon A. de Boer
Marjon A. de Boer
Ekaterina S. JordanovaEkaterina S. Jordanova
Ekaterina S. Jordanova
GKGemma G. Kenter
Gemma G. Kenter
APAlexander A. Peters
Alexander A. Peters
WCWillem Corver
Willem Corver
GFGert Jan Fleuren
Gert Jan Fleuren
Purpose: Cervical cancer is now known to be caused by infection with an oncogenic type of the human papillomavirus (HPV). However, little is known about the continued role of HPV once cancer has been established. Here, we describe the quantitative relation between HPV DNA copy number and mRNA expression of the viral oncogenes (E6 and E7) and the prognostic value of both measures in cervical cancer patients. Experimental Design: We studied the number of viral DNA copies and the level of HPV E6/E7 mRNA expression in 75 HPV 16–positive or HPV 18–positive International Federation of Gynecology and Obstetrics stage Ib and IIa cervical cancer patients. Measurements were done with quantitative PCR. DNA copy number analysis was done on pure tumor cell samples enriched with flow sorting. mRNA expression data were compensated for the percentage of tumor cells included. Results: The number of viral DNA copies was not predictive of survival in cervical cancer patients. In contrast, high HPV E6/E7 mRNA expression was strongly related to an unfavorable prognosis (P = 0.006). In a multivariate Cox model for overall survival, including all known prognostic variables and stratified for HPV type, the level of E6/E7 mRNA expression was an independent prognostic indicator, second only to lymph node status. No correlation was observed between DNA copy number and the level of HPV E6/E7 mRNA expression, which reflects that not all DNA copies are equally transcriptionally active. Conclusions: Cervical cancer patients with high HPV E6/E7 oncogene mRNA expression have a worse survival independently from established prognostic factors.